Trial Profile
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Antineoplastics; Platinum complexes
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MERMAID-1
- Sponsors AstraZeneca; AstraZeneca AB
- 08 Mar 2024 This trial has been Discontinued in Italy, According to European Clinical Trials Database record.
- 11 Feb 2024 This trial has been Discontinued in Sweden, According to European Clinical Trials Database record.
- 07 Dec 2023 This trial has been Discontinued in Hungary (Global end date: 31 Aug 2023).